U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Grade 1 Xerostomia, CTCAE

MedGen UID:
286790
•Concept ID:
C1560328
•
Finding
Synonym: CTCAE Grade 1 Dry mouth/salivary gland (xerostomia)

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVGrade 1 Xerostomia, CTCAE

Professional guidelines

PubMed

Effects of treatment intensification on acute local toxicity during radiotherapy for head and neck cancer: prospective observational study validating CTCAE, version 3.0, scoring system.
Palazzi M, Tomatis S, Orlandi E, Guzzo M, Sangalli C, Potepan P, Fantini S, Bergamini C, Gavazzi C, Licitra L, Scaramellini G, Cantu' G, Olmi P
Int J Radiat Oncol Biol Phys 2008 Feb 1;70(2):330-7. Epub 2007 Sep 19 doi: 10.1016/j.ijrobp.2007.06.022. PMID: 17881148

Recent clinical studies

Etiology

Long-term survival outcomes of salvage [(225)Ac]Ac-PSMA-617 targeted alpha therapy in patients with PSMA-expressing end-stage metastatic castration-resistant prostate cancer: a real-world study.
Ballal S, Yadav MP, Satapathy S, Raju S, Tripathi M, Damle NA, Sahoo RK, Bal C
Eur J Nucl Med Mol Imaging 2023 Oct;50(12):3777-3789. Epub 2023 Jul 18 doi: 10.1007/s00259-023-06340-y. PMID: 37462775
Salivary inflammatory mediators as biomarkers for oral mucositis and oral mucosal dryness in cancer patients: A pilot study.
Kiyomi A, Yoshida K, Arai C, Usuki R, Yamazaki K, Hoshino N, Kurokawa A, Imai S, Suzuki N, Toyama A, Sugiura M
PLoS One 2022;17(4):e0267092. Epub 2022 Apr 27 doi: 10.1371/journal.pone.0267092. PMID: 35476641Free PMC Article
Hyperbaric oxygen treatment of mandibular osteoradionecrosis: Combined data from the two randomized clinical trials DAHANCA-21 and NWHHT2009-1.
Forner LE, Dieleman FJ, Shaw RJ, Kanatas A, Butterworth CJ, Kjeller G, Alsner J, Overgaard J, Hillerup S, Hyldegaard O, Arnell P, von Buchwald C, Kaanders JHAM, Smeele LE, Specht L, Johansen J, Witjes MJH, Merkx MAW, Jansen EC
Radiother Oncol 2022 Jan;166:137-144. Epub 2021 Nov 26 doi: 10.1016/j.radonc.2021.11.021. PMID: 34843843
Xerostomia: an immunotherapy-related adverse effect in cancer patients.
Bustillos H, Indorf A, Alwan L, Thompson J, Jung L
Support Care Cancer 2022 Feb;30(2):1681-1687. Epub 2021 Sep 25 doi: 10.1007/s00520-021-06535-9. PMID: 34562169
Radiotherapy for cutaneous head and neck cancer and parotid tumours: a prospective investigation of treatment-related acute swallowing and toxicity patterns.
Moroney LB, Helios J, Ward EC, Crombie J, Burns CL, Yeo SQ, Pelecanos A, Spurgin AL, Blake C, Kenny L, Chua B, Hughes BGM
Support Care Cancer 2019 Feb;27(2):573-581. Epub 2018 Jul 17 doi: 10.1007/s00520-018-4352-5. PMID: 30019149

Diagnosis

Primary and adjuvant intensity-modulated radiotherapy in oropharyngeal carcinoma patients from a single institution.
Hauswald H, Petrow E, Roeder F, Debus J, Zwicker F, Huber PE
J Cancer Res Ther 2024 Jan 1;20(1):375-382. Epub 2023 Apr 4 doi: 10.4103/jcrt.jcrt_2178_22. PMID: 38554349
Predicting acute radiation induced xerostomia in head and neck Cancer using MR and CT Radiomics of parotid and submandibular glands.
Sheikh K, Lee SH, Cheng Z, Lakshminarayanan P, Peng L, Han P, McNutt TR, Quon H, Lee J
Radiat Oncol 2019 Jul 29;14(1):131. doi: 10.1186/s13014-019-1339-4. PMID: 31358029Free PMC Article
Definitive radiotherapy vs. postoperative radiotherapy for lower gingival carcinomas of the mandible : A single-center report about outcome and toxicity.
Lang K, Akbaba S, Held T, Kargus S, Horn D, Bougatf N, Bernhardt D, Freier K, Rieken S, Debus J, Adeberg S
Strahlenther Onkol 2019 Sep;195(9):819-829. Epub 2019 Jul 2 doi: 10.1007/s00066-019-01484-z. PMID: 31267170
A randomized phase II/III study of adverse events between sequential (SEQ) versus simultaneous integrated boost (SIB) intensity modulated radiation therapy (IMRT) in nasopharyngeal carcinoma; preliminary result on acute adverse events.
Songthong AP, Kannarunimit D, Chakkabat C, Lertbutsayanukul C
Radiat Oncol 2015 Aug 8;10:166. doi: 10.1186/s13014-015-0472-y. PMID: 26253488Free PMC Article

Therapy

Long-term survival outcomes of salvage [(225)Ac]Ac-PSMA-617 targeted alpha therapy in patients with PSMA-expressing end-stage metastatic castration-resistant prostate cancer: a real-world study.
Ballal S, Yadav MP, Satapathy S, Raju S, Tripathi M, Damle NA, Sahoo RK, Bal C
Eur J Nucl Med Mol Imaging 2023 Oct;50(12):3777-3789. Epub 2023 Jul 18 doi: 10.1007/s00259-023-06340-y. PMID: 37462775
Hyperbaric oxygen treatment of mandibular osteoradionecrosis: Combined data from the two randomized clinical trials DAHANCA-21 and NWHHT2009-1.
Forner LE, Dieleman FJ, Shaw RJ, Kanatas A, Butterworth CJ, Kjeller G, Alsner J, Overgaard J, Hillerup S, Hyldegaard O, Arnell P, von Buchwald C, Kaanders JHAM, Smeele LE, Specht L, Johansen J, Witjes MJH, Merkx MAW, Jansen EC
Radiother Oncol 2022 Jan;166:137-144. Epub 2021 Nov 26 doi: 10.1016/j.radonc.2021.11.021. PMID: 34843843
Efficacy and safety of (225)Ac-PSMA-617 targeted alpha therapy in metastatic castration-resistant Prostate Cancer patients.
Yadav MP, Ballal S, Sahoo RK, Tripathi M, Seth A, Bal C
Theranostics 2020;10(20):9364-9377. Epub 2020 Jul 23 doi: 10.7150/thno.48107. PMID: 32802197Free PMC Article
Predicting acute radiation induced xerostomia in head and neck Cancer using MR and CT Radiomics of parotid and submandibular glands.
Sheikh K, Lee SH, Cheng Z, Lakshminarayanan P, Peng L, Han P, McNutt TR, Quon H, Lee J
Radiat Oncol 2019 Jul 29;14(1):131. doi: 10.1186/s13014-019-1339-4. PMID: 31358029Free PMC Article
First Experience With 177Lu-PSMA-617 Therapy for Advanced Prostate Cancer in the Netherlands.
van Kalmthout L, Braat A, Lam M, van Leeuwaarde R, Krijger G, Ververs T, Mehra N, Bins A, Hunting J, de Keizer B
Clin Nucl Med 2019 Jun;44(6):446-451. doi: 10.1097/RLU.0000000000002561. PMID: 30985436

Prognosis

Primary and adjuvant intensity-modulated radiotherapy in oropharyngeal carcinoma patients from a single institution.
Hauswald H, Petrow E, Roeder F, Debus J, Zwicker F, Huber PE
J Cancer Res Ther 2024 Jan 1;20(1):375-382. Epub 2023 Apr 4 doi: 10.4103/jcrt.jcrt_2178_22. PMID: 38554349
Long-term survival outcomes of salvage [(225)Ac]Ac-PSMA-617 targeted alpha therapy in patients with PSMA-expressing end-stage metastatic castration-resistant prostate cancer: a real-world study.
Ballal S, Yadav MP, Satapathy S, Raju S, Tripathi M, Damle NA, Sahoo RK, Bal C
Eur J Nucl Med Mol Imaging 2023 Oct;50(12):3777-3789. Epub 2023 Jul 18 doi: 10.1007/s00259-023-06340-y. PMID: 37462775
Xerostomia: an immunotherapy-related adverse effect in cancer patients.
Bustillos H, Indorf A, Alwan L, Thompson J, Jung L
Support Care Cancer 2022 Feb;30(2):1681-1687. Epub 2021 Sep 25 doi: 10.1007/s00520-021-06535-9. PMID: 34562169
Efficacy and safety of (225)Ac-PSMA-617 targeted alpha therapy in metastatic castration-resistant Prostate Cancer patients.
Yadav MP, Ballal S, Sahoo RK, Tripathi M, Seth A, Bal C
Theranostics 2020;10(20):9364-9377. Epub 2020 Jul 23 doi: 10.7150/thno.48107. PMID: 32802197Free PMC Article
Predicting acute radiation induced xerostomia in head and neck Cancer using MR and CT Radiomics of parotid and submandibular glands.
Sheikh K, Lee SH, Cheng Z, Lakshminarayanan P, Peng L, Han P, McNutt TR, Quon H, Lee J
Radiat Oncol 2019 Jul 29;14(1):131. doi: 10.1186/s13014-019-1339-4. PMID: 31358029Free PMC Article

Clinical prediction guides

Long-term survival outcomes of salvage [(225)Ac]Ac-PSMA-617 targeted alpha therapy in patients with PSMA-expressing end-stage metastatic castration-resistant prostate cancer: a real-world study.
Ballal S, Yadav MP, Satapathy S, Raju S, Tripathi M, Damle NA, Sahoo RK, Bal C
Eur J Nucl Med Mol Imaging 2023 Oct;50(12):3777-3789. Epub 2023 Jul 18 doi: 10.1007/s00259-023-06340-y. PMID: 37462775
Salivary inflammatory mediators as biomarkers for oral mucositis and oral mucosal dryness in cancer patients: A pilot study.
Kiyomi A, Yoshida K, Arai C, Usuki R, Yamazaki K, Hoshino N, Kurokawa A, Imai S, Suzuki N, Toyama A, Sugiura M
PLoS One 2022;17(4):e0267092. Epub 2022 Apr 27 doi: 10.1371/journal.pone.0267092. PMID: 35476641Free PMC Article
Efficacy and safety of (225)Ac-PSMA-617 targeted alpha therapy in metastatic castration-resistant Prostate Cancer patients.
Yadav MP, Ballal S, Sahoo RK, Tripathi M, Seth A, Bal C
Theranostics 2020;10(20):9364-9377. Epub 2020 Jul 23 doi: 10.7150/thno.48107. PMID: 32802197Free PMC Article
Predicting acute radiation induced xerostomia in head and neck Cancer using MR and CT Radiomics of parotid and submandibular glands.
Sheikh K, Lee SH, Cheng Z, Lakshminarayanan P, Peng L, Han P, McNutt TR, Quon H, Lee J
Radiat Oncol 2019 Jul 29;14(1):131. doi: 10.1186/s13014-019-1339-4. PMID: 31358029Free PMC Article
Radiotherapy for cutaneous head and neck cancer and parotid tumours: a prospective investigation of treatment-related acute swallowing and toxicity patterns.
Moroney LB, Helios J, Ward EC, Crombie J, Burns CL, Yeo SQ, Pelecanos A, Spurgin AL, Blake C, Kenny L, Chua B, Hughes BGM
Support Care Cancer 2019 Feb;27(2):573-581. Epub 2018 Jul 17 doi: 10.1007/s00520-018-4352-5. PMID: 30019149

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...